Deciphera Pharmaceuticals, Inc.

Good morning, everyone, and welcome to Decipher's Pharmaceuticals First Quarter 2022 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Megan Myers, Senior Vice President at Argot Partners. Megan?

Thank you, Operator. Welcome, and thank you for joining us today to discuss Decipher's First Quarter 2022 Financial Results. I'm Megan Myers with Argot Partners. With me this morning to discuss the financial results and provide a general corporate update are Steve Herter, President and Chief Executive Officer, Dan Martin, Chief Commercial Officer, Matt Sherman, Chief Medical Officer, Margarita Duarte, Head of International, and Tucker Kelly, Chief Financial Officer. Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the St. Harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this call include our expectations for our preclinical and clinical programs, our commercialization of Kinloch, and 2022 guidance. Forward-looking statements made on this call involved substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statement, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include those set forth in our most recent quarterly report on Form 10-Q, as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements. Following this call, a replay will be available on the company's website www.deciphera.com. With that, I will now turn the call over to Steve Herder, President and Chief Executive Officer of Deciphera. Steve?

Thank you, Megan, and good morning, everyone. Thank you for joining us today as we provide an update from the first quarter, review our financial results, and look forward to the rest of the year ahead. We have made significant progress toward our 2022 goals so far this year, delivering strong commercial performance for Kenlock and rapidly advancing our pipeline of product candidates. with first and best in class potential. On today's call, Dan Martin, our Chief Commercial Officer, will share more details about our U.S. commercial performance for the quarter and how we have successfully established Kinloch as the clear standard of care and fourth line GIST. Margarita Duarte, our Head of the International Business, will provide more details about the strong launch momentum of Kinloch in Germany and our plans for delivering this breakthrough therapy to patients in other parts of the world. Beyond Kinloch, we are making substantial progress as we advance our clinical stage portfolio and explore the full potential of DCC3116, our first-in-class inhibitor of the ALK kinase, which is the initiating factor in the autophagy pathway. Matt Sherman, our chief medical officer, will provide an update on the Vimseltinib development program now that the pivotal Phase III motion study is actively enrolling patients globally. Last month, at the American Association of Cancer Research annual meeting, we presented exciting new preclinical data with 3116 in combination with KRAS G12C inhibitors and lung cancer models. These data, together with the body of data we have previously generated, underscore the broad role of autophagy in cancer and the potential for DCC 3116 to benefit a significant number of patients with cancer worldwide. We look forward to presenting the first data from the ongoing Phase 1 study later this year and then exploring the potential benefit of combining 3116 with MEK and KRAS G12C inhibitors. Finally, we are very pleased with the outcome of our follow-on stock offering last week. We are now in an even stronger financial position, allowing us to rapidly advance our pipeline to build long-term shareholder value and deliver important new medicines to patients. I'll now turn the call over to Matt Sherman, our Chief Medical Officer, to provide an update on our R&D efforts. Matt?